Physician profile
Robert Emil Ford
NPI 1790753242
$3,424.83
in general payments reported to CMS, 2019-2025
32 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $751 · 2021: $767 · 2022: $444 · 2023: $335 · 2024: $366 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $971.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $387.86 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $375.53 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $270.65 | 2020-2025 | Kisunla, Mounjaro, Jardiance |
| Abbvie INC. | $259.35 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $243.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $99.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $62.49 | 2021-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $61.35 | 2020-2021 | |
| Amgen INC. | $59.27 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.01 | 2022-2024 | Zoryve |
| Allergan, INC. | $54.42 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.24 | 2019 | |
| Lundbeck LLC | $45.03 | 2023-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $42.60 | 2021 | |
| Ibsa Pharma INC. | $33.35 | 2024-2025 | Tirosint, Licart, Flector |
| Amarin Pharma, INC. | $32.41 | 2019-2020 | |
| Aytu Biopharma, INC. | $29.92 | 2019 | |
| Esperion Therapeutics, INC. | $25.24 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $22.82 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $21.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.57 | 2023 | Eliquis |
| Gilead Sciences, INC. | $19.32 | 2019 | |
| Optinose US, INC. | $18.76 | 2025 | |
| Radius Health, INC. | $17.35 | 2022 | |
| Genentech USA, INC. | $16.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.55 | 2022 | |
| Eisai INC. | $12.68 | 2021 | |
| Melinta Therapeutics, LLC | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.